Novel Approaches to Target MECOM/EVI1 in AML

Recruiting now · Not applicable

Conditions studied: AML, Adult

In brief

This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.

Key facts

Study ID

NCT05839392

Run by

Gruppo Italiano Malattie EMatologiche dell'Adulto

People needed

24

Starts

2023-12-13

Expected to finish

2026-12-01

Last updated by the study team

2023-12-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• AML with MECOM or atypical 3q26 rearrangements.
• Age ≥18.
• Signed written informed consent according to ICH/EU/GCP and national local laws.

You may not qualify if…

• None

Where it is running

• Ematologia — Piacenza, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.